Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BMY

3 Undervalued Healthcare Stocks With High Potential

The healthcare sector is expected to grow rapidly due to the growing need for precision drugs, the rising elderly population, government initiatives, and increasing chronic diseases. Against this backdrop, investors could consider buying fundamentally strong, undervalued healthcare stocks such as AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Gilead Sciences (GILD). Read…

StockNews.com

Eli Lilly Stock: Is LLY Outperforming the Healthcare Sector?

Eli Lilly has outperformed the healthcare sector over the past three months, but analysts remain cautiously optimistic about the stock’s prospects.

Barchart

Dividend Stability and Growth in Pharma: Pfizer (PFE) vs. Bristol-Myers Squibb (BMY)

The pharma sector is primed for solid growth owing to technological advancements, growing healthcare needs, and a rise in chronic diseases. Given this backdrop, let’s analyze the fundamentals of pharmaceutical stocks Pfizer (PFE) and Bristol-Myers Squibb (BMY) to determine which of these stocks offer better dividend stability and growth. Read…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Do Wall Street Analysts Like Bristol-Myers Squibb Stock?

Bristol-Myers Squibb stock has significantly trailed the broader market this year, and Wall Street remains wary on the stock’s prospects.

Barchart

3 Pharma Stocks Primed for May Investment Opportunities

The pharma industry is poised for tremendous growth driven by surging healthcare needs, the introduction of groundbreaking medications, and relentless technological innovation. Hence, quality pharma stocks Collegium Pharmaceutical (COLL), Green Thumb Industries (GTBIF), and Bristol-Myers Squibb (BMY) emerge as prime investment options this month. Read more….

StockNews.com

3 Pharma Stocks to Snatch up During Market Dips

The pharmaceutical industry is undergoing rapid growth and expansion, driven by rising medical needs, favorable regulatory measures, and the implementation of pharma 4.0. Hence, investors could snatch up quality pharma stocks Bristol-Myers Squibb (BMY), Spero Therapeutics (SPRO), and OptiNose (OPTN) for steady returns during market dips. Read more.

StockNews.com

3 A-Rated Pharma Stocks to Boost Your Bottom Line

The pharmaceutical industry is experiencing rapid growth thanks to healthcare demand, regulatory initiatives, and technological adoption in drug discovery and development. Hence, it could be wise to invest in pharma stocks Ipsen (IPSEY), Bristol-Myers (BMY), and Taro Pharmaceutical (TARO) to drive your bottom line. These stocks are rated A (Strong…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

4 Pharma Titans Making Waves in Wall Street

The pharma industry is well-positioned to remain buoyed, owing to the rise in chronic diseases, a growing elderly population, and the integration of advanced technologies. Given this backdrop, quality pharma stocks Bristol-Myers Squibb Company (BMY), Johnson & Johnson (JNJ), Novartis AG (NVS), and Merck & Co. (MRK), making waves in…

StockNews.com

Bristol Myers Squibb Reports Strong Q4 Results

Bristol Myers Squibb (BMY) reports strong Q4 results, faces biosimilar competition, but shows growth potential.

Top News

Pharma Stocks Analysis: Grab, Hold, or Sell?

Despite economic pressures and intensified competition, government incentives and drug innovations are fueling growth in the pharma sector. So, let us delve into the analysis of leading pharma stocks Bristol-Myers Squibb (BMY), Collegium Pharmaceutical (COLL), Pfizer (PFE), and Vaxcyte (PCVX), assessing whether to Grab, Hold, or Sell the stocks amid…

StockNews.com

3 Growth Pharma Stocks to Guard Your Portfolio

The pharma industry is experiencing significant growth, fueled by rising demand for personalized medicines, a revolutionary wave of drug development and robust government support. Therefore, it could be wise to consider fundamentally strong pharma stocks Zoetis (ZTS), Bristol-Myers Squibb (BMY), and Teva Pharmaceutical Industries (TEVA) to guard your portfolio. Read…

StockNews.com

Bristol Myers Stock Yo-Yoes, Trying To Avoid A Fourth Day In The Red, On So-So Earnings

Bristol Myers Squibb topped Wall Street's fourth-quarter expectations on Friday, but BMY stock yo-yoed and pulled back from strong gains.

Investors Business Daily

Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%

Bristol Myers Squibb said it would acquire cancer drug developer RayzeBio in a $4.1 billion deal. RYZB stock soared; BMY stock traded slightly lower.

Investors Business Daily

Analyzing December Profit Potential for the Top 4 Pharma Stocks

The global pharmaceutical market is witnessing robust growth, fueled by an escalating demand for healthcare services amid a burgeoning and aging population. Hence, fundamentally solid pharma stocks Novartis (NVS), Bristol-Myers Squibb (BMY), AbbVie (ABBV), and Taro Pharmaceutical (TARO) might be solid buys for gains this month. Read more.

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

4 Long-Duration Unusually Active Call Options Ranked Best to Worst

Wall Street aims to close out a third consecutive winning week. Several retailers' stocks have popped in early Friday trading. Four long-duration call options have caught my attention. I’ve ranked them from best to worst.

StockNews.com

3 Booming Pharma Stocks Making Waves in the Industry

The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Given this backdrop, it could be wise to buy Roche Holding (RHHBY), AstraZeneca (AZN) and Bristol-Myers Squibb (BMY), which look poised for steady returns. Keep reading.

Barchart

2 High-Yield Value Stocks to Buy Now

Here's a look at two dividend value stocks with high yields that Wall Street recommends buying.

StockNews.com

3 Pharma Stocks to Capitalize on With Potential Upside

The pharma industry’s prospects look bright, thanks to rising demand for innovative drugs. Thus, pharma stocks with potential upside, like GSK plc (GSK), Johnson & Johnson (JNJ), and Bristol-Myers Squibb Company (BMY), could be wise investments to capitalize on right now. Read on….

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Bristol Myers Skids After Pushing Back A Key $10 Billion Sales Milestone

Bristol Myers Squibb pushed back sales expectations for its new drugs by a year early Thursday, and BMY stock tumbled.

Barchart

3 Buy-Rated S&P 500 Stocks to Scoop Up Near 52-Week Lows

Beaten-down blue-chip stocks, such as United Parcel Services, look poised to deliver double-digit returns to shareholders in the next year.

StockNews.com

Secure Your Portfolio With These 3 Pharma Stocks

With rising global healthcare needs, investing in fundamentally sound pharma stocks AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and Astellas Pharma (ALPMY) could help secure your portfolio by offering stability during economic uncertainties. Read on….

StockNews.com

3 Pharmaceutical Stocks to Watch

The pharmaceutical industry is anticipated to grow due to rising chronic diseases and an aging population. Given the industry's strong long-term prospects, quality stocks Novo Nordisk (NVO), Novartis (NVS), and Bristol-Myers Squibb (BMY) could be worth adding to your watchlist. Continue reading….

Barchart

Short Straddle Screener Results For April 13th

The screener shows some interesting short straddle trades on popular stocks such as BMY, AAPL, VZ, CRM, GOOG, INTC, PANW, XOM and TSLA.

StockNews.com

Stay Forever Young With These 3 Pharmaceutical Stocks

Despite macroeconomic headwinds, the pharmaceutical industry is anticipated to stay buoyed in the foreseeable future, owing to rising healthcare spending. Against this backdrop, we think the strong fundamentals of Novo Nordisk (NVO), Bristol-Myers Squibb (BMY), and Takeda Pharmaceutical (TAK) make them wise portfolio additions. Read on….

StockNews.com

3 Large-Cap Pharma Stocks to Protect Your Portfolio Through 2023

The worst banking crisis since 2008 could not stop the Fed from raising the benchmark interest rate. The possibility of further policy tightening and strict lending standards for banks might push the economy into a recession this year. Therefore, investing in large-cap pharma stocks Johnson & Johnson (JNJ), Merck &…

1 2 3 4 5

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

Neha PanjwaniFrom

97 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.